Pulse Biosciences (Nasdaq:PLSE) announced today that it entered into a collaboration with CardioNXT to support its AFib treatment. The collaboration supports Pulse Biosciences’ planned first-in-human study of its pulsed-field ablation technology. Hayward, California-based Pulse develops a proprietary nanosecond pulsed-field ablation (nsPFA) cardiac catheter to treat AFib. Pulse and CardioNXT plan for their partnership to integrate the […]
CardioNXT
Farapulse founder’s Field Medical partners with CardioNXT on novel pulsed-field ablation tech
Field Medical and CardioNXT announced a strategic collaboration to provide what they say is a first-of-its-kind pulsed-field ablation (PFA) therapy. The two companies plan to provide a purpose-built PFA therapy integrated with 3D mapping and navigation. According to a news release, both teams bring decades of experience in pioneering novel PFA and navigation technologies. Their […]
Ex-Medtronic CEO Hawkins backs CardioNXT in $2m round
A former CEO of Medtronic (NYSE:MDT) and a well-known medical device industry veteran got in on a $2.1 million funding round for CardioNXT, which is developing new tools to treat atrial fibrillation. Ex-Medtronic chief William Hawkins III and Zyga CEO James Bullock led the round, joined by Piedmont Capital Partners and prior backer Solas BioVentures. […]
CardioNXT raises $1.5m for novel cardiac ablation tech
Heart focused medical-technology company CardioNXT said today it raised $1.5 million in equity funding to support its platform of cardiac arrhythmia products. CardioNXT is developing products to improve the understanding of complex cardiac arrhythmias such as atrial fibrillation and to reduce the cost of cardiac catheter ablation procedures, the company said. Funds in the round […]